HORSHAM, PA — Myonex has announced the recent completion of its acquisition of SaveWay Compounding Pharmacy, based in Newark, Delaware. The pharmacy will continue to operate under its established name as a Myonex company, marking a significant step forward in the expansion of Myonex’s direct-to-patient (DTP) and home healthcare provider (HHP) capabilities across the United States.
This acquisition is poised to broaden patient access to trial medications and necessary equipment, reinforcing Myonex’s commitment to supporting clinical trial sponsors with innovative trial designs. By integrating SaveWay’s pharmacy capabilities, Myonex aims to bolster its existing clinical supplies solutions within the U.S., offering enhanced drug sourcing and DTP options nationwide.
James Lovett, Chief Executive Officer at Myonex, highlighted the acquisition’s role in strengthening the company’s ability to support decentralized clinical trials (DCT) and hybrid studies. “SaveWay complements our market-leading CTRx™ platform, ensuring a comprehensive suite of prescription-based supply options for investigational medicinal products (IMP) and commercial drug access throughout the U.S.,” said Lovett.
The move is not just an expansion of services but also a strategic alignment with current trends in clinical trials, focusing on patient-centric approaches and the facilitation of DCTs. Pradeep Chilakapati, RPh, Managing Partner and Pharmacist at SaveWay, expressed enthusiasm for the growth opportunities this partnership brings. “Joining forces with Myonex allows us to extend our reach and impact in serving patients across the U.S. in clinical trials, dispensing investigational medicinal products, commercial medications, and specialized compounded medications directly to patients,” Chilakapati remarked.
The acquisition of SaveWay, following closely on the heels of the purchase of Creapharm, signals Myonex’s accelerated commitment to enhancing flexibility, reliability, and the overall patient experience in clinical trials. This series of strategic acquisitions underscores Myonex’s position as a prominent industry partner with one of the most comprehensive clinical trial supply service offerings globally.
Advisory roles in the acquisition were filled by Crosstree, serving as Myonex’s exclusive financial advisor, and Troutman Pepper, providing legal counsel. These partnerships reflect the strategic planning and careful execution behind Myonex’s expansion efforts.
The implications of this acquisition extend beyond the immediate expansion of services. By facilitating easier access to trial medications and supporting the operational needs of DCTs, Myonex is set to play a crucial role in the future of clinical research. This approach not only enhances the efficiency and reach of clinical trials but also prioritizes the convenience and care of participants, potentially leading to higher engagement rates and more robust study outcomes.
As the pharmaceutical and healthcare industries continue to evolve towards more patient-centered and technologically integrated models, companies like Myonex are leading the charge. Their efforts to streamline clinical trial processes and improve patient experiences are essential components in the broader push for faster, more effective medical advancements.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.